Itulazax (Betula Verrucosa (108))

Betula verrucosa in Itulazax acts as a sublingual immunotherapy agent. The allergen is presented to immune cells in the oral mucosa, promoting regulatory T‑cell development and increasing IgG4 antibodies while decreasing IgE‑mediated responses, thereby inducing long‑term tolerance to birch pollen.

The dosing regimen for Itulazax is individualized. A qualified healthcare professional determines the starting dose, escalation schedule, and maintenance dose based on the patient’s sensitivity, age, and clinical response. Patients should follow the prescriber’s instructions precisely.

Safety data for Itulazax in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with pregnant or nursing patients before prescribing.

To order Itulazax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Itulazax provides sublingual allergen immunotherapy, which differs from symptomatic antihistamines or nasal corticosteroids that only relieve symptoms. Compared with subcutaneous immunotherapy, the sublingual route offers self‑administration at home and a lower risk of systemic reactions, while still delivering disease‑modifying tolerance.

Itulazax should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme temperatures. Do not refrigerate unless specifically instructed by the manufacturer.

Itulazax is administered sublingually. The patient places the prescribed dose under the tongue and holds it for the recommended time before swallowing, allowing the allergen to be absorbed through the oral mucosa. Administration should be performed under medical guidance, especially during the initial dosing period.

The most serious risks include systemic allergic reactions such as anaphylaxis, angioedema of the lips or tongue, and respiratory distress. Patients should be observed after the first dose and instructed to seek immediate medical care if they experience any signs of a severe reaction.

Itulazax is contraindicated in individuals with a known severe anaphylactic reaction to birch pollen or any component of the formulation. Patients with uncontrolled asthma or those receiving beta‑blockers should use it only under close medical supervision, and it should be avoided in patients with a history of severe angioedema.